Physicians' Academy for Cardiovascular Education

Understanding Diabetic Kidney Disease: What are the best options for clinical management?

Lecture - July 30, 2016 - Asian Interchange on Diabetes meeting - Per-Henrik Groop, MD – University of Helsinki, Helsinki, Finland

Dr. Per-Henrik Groop outlines that diabetic kidney disease is common and associated with a grim prognosis. Optimal glucose control is central to limiting the risk of renal complications. Newer antidiabetic drugs can play a welcome role to optimally treat these patients.

This lecture was recorded during the Asian Interchange on Diabetes meeting, held in Bangkok on July 30-31, 2016

Video navigation menu

  • Kidney disease in diabetes greatly enhances risk of CV morbidity and mortality 1:52
  • Importance of blood glucose control - a five finger rule to optimally treat diabetic kidney disease 8:22
  • Achieving glucose control without causing harm - DPP4 inhibitors and GLP-1 agonists and renal function 12:21
  • Pre-specified renal endpoints with SGLT2 inhibition in the EMPA-REG OUTCOME trial 20:03
  • Implications of the renal results of empagliflozin 22:34
  • Why does empagliflozin work so well and how can we benefit from it in clinical practice? 24:00

The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: